

ASTELLAS - FDA Accepts Mirabegron NDA - Signals Elimination of Glaucoma Concerns - Approval Should be on Time!

https://marketpublishers.com/r/ADCB2D0E99EEN.html

Date: November 2011

Pages: 3

Price: US\$ 90.00 (Single User License)

ID: ADCB2D0E99EEN

Abstracts

FDA has accepted NDA of mirabegron (first in class ?3-AR agonist, overactive bladder syndrome, OAB). Glaucoma safety issues had surfaced in Nov-10 and raised concerns over the fate of this important candidate for Astellas whose aim is to maintain its leadership in urinary segment after Harnal and VESIcare. After reviewing the data in March, 2011 and meeting the management, we had expected mirabegron to come out clean and reach the market on time. We are expecting, mirabegron will be targeted 30% of patients on antimuscarinic therapy who experience anti-cholinergic SEs and should come at premium pricing.



Contents

COMPANIES MENTIONED

ASTELLAS



I would like to order

Product name: ASTELLAS - FDA Accepts Mirabegron NDA - Signals Elimination of Glaucoma Concerns

- Approval Should be on Time!

Product link: https://marketpublishers.com/r/ADCB2D0E99EEN.html

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/ADCB2D0E99EEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

